Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.
Over the past year Eli Lilly (LLY) stock returned about 52%, moving from $757.59 to $1,154.97 while the S&P 500 returned 17.7%
A gap that size looks like something blindsided the market. Nothing did. The story it moved on was laid out in public, with dates attached, months before the price caught up.
The Franchise Scaled, Then The Pill Arrived Two things carry the year, and only one of them is new. Revenue rose 56% year over year in the first quarter of 2026, non-GAAP earnings per share reached $8.55 against $3.34 a year earlier, and the non-GAAP performance margin hit 50%, roughly seven percentage points above the prior-year quarter. Management raised both ends of full-year 2026 revenue guidance by $2 billion, putting the midpoint at 28% growth over 2025, and tied that raise to strong underlying performance in the quarter rather than to the new medicine, which had three weeks of data at the time.